Differential Diagnosis in Immune Checkpoint Inhibitors Neurotoxicity

Overview

Journal J Neurol

Date 2025 Jan 15

PMID 39812686

Authors

Catherine R Garcia

Ian J Robertson

Timothy A Gregory

Anza Zahid

Behrang Amini

Carlos Kamiya-Matsuoka

Sudhakar Tummala

Affiliations

Soon will be listed here.

Abstract

Background: Neurologic symptoms seen in patients receiving immune checkpoint inhibitors (ICI) may not be entirely caused by immunotoxicity. We aim to highlight these confounding conditions through clinical cases to encourage early recognition and management.

Methods: We describe a series of seven cases from our institution that were treated with ICI and presented with Neurologic symptoms and were diagnosed with superimposed conditions beyond immunotoxicity.

Results: A total of 7 cases are described that include acute motor axonal neuropathy with vitamin B12 deficiency, lumbosacral radiculopathy with Wernicke's, Herpes simplex virus (HSV) encephalitis reactivation, central nervous system vasculitis with renal vasculitis, myositis with fasciitis, myositis with fixed clinical deficit at resolution, and synovitis with accompanying carpal tunnel syndrome. Primary cancer site included lung adenocarcinoma (2/7), melanoma (4/7), and oropharyngeal squamous cell carcinoma (1/7). All patients had received treatment with more than one ICI. Median number of cycles prior to neurotoxicity was 3 cycles.

Discussion: Neurologic symptoms seen in patients receiving ICI may include other causes beyond immunotoxicity.

References

Farooq M, Aqeel S, Lingamaneni P, Pichardo R, Jawed A, Khalid S . Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022; 5(4):e227722. PMC: 9020216. DOI: 10.1001/jamanetworkopen.2022.7722. View

Scott E, Baines A, Gong Y, Moore Jr R, Pamuk G, Saber H . Trends in the approval of cancer therapies by the FDA in the twenty-first century. Nat Rev Drug Discov. 2023; 22(8):625-640. DOI: 10.1038/s41573-023-00723-4. View

Marini A, Bernardini A, Gigli G, Valente M, Muniz-Castrillo S, Honnorat J . Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Neurology. 2021; 96(16):754-766. DOI: 10.1212/WNL.0000000000011795. View

Farina A, Birzu C, Elsensohn M, Picca A, Muniz-Castrillo S, Vogrig A . Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun. 2023; 5(3):fcad169. PMC: 10306160. DOI: 10.1093/braincomms/fcad169. View

Tiu B, Zubiri L, Iheke J, Pahalyants V, Theodosakis N, Ugwu-Dike P . Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. J Immunother Cancer. 2022; 10(6). PMC: 9204442. DOI: 10.1136/jitc-2022-004670. View

Lommerts J, Bekkenk M, Luiten R . Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion. Expert Opin Drug Saf. 2021; 20(8):883-888. DOI: 10.1080/14740338.2021.1915279. View

Boutros A, Bottini A, Rossi G, Tanda E, Spagnolo F, Barletta G . Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature. ESMO Open. 2023; 8(1):100791. PMC: 9958259. DOI: 10.1016/j.esmoop.2023.100791. View

Ruggiero R, Di Napoli R, Balzano N, Ruggiero D, Riccardi C, Anatriello A . Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management. Expert Rev Clin Pharmacol. 2023; 16(5):423-434. DOI: 10.1080/17512433.2023.2211262. View

Zubiri L, Molina G, Mooradian M, Cohen J, Durbin S, Petrillo L . Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. 2021; 9(9). PMC: 8454442. DOI: 10.1136/jitc-2021-002886. View

10.

Schneider B, Naidoo J, Santomasso B, Lacchetti C, Adkins S, Anadkat M . Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021; 39(36):4073-4126. DOI: 10.1200/JCO.21.01440. View

11.

Pepys J, Stoff R, Ramon-Gonen R, Ben-Betzalel G, Grynberg S, Frommer R . Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma. Neurology. 2023; 101(24):e2472-e2482. PMC: 10791056. DOI: 10.1212/WNL.0000000000207632. View

12.

Spain L, Tippu Z, Larkin J, Carr A, Turajlic S . How we treat neurological toxicity from immune checkpoint inhibitors. ESMO Open. 2019; 4(Suppl 4):e000540. PMC: 6678012. DOI: 10.1136/esmoopen-2019-000540. View

13.

Damato V, Berretta A, Ramanathan S, Michael S, Coupe N, Payne M . Association Between a Distinctive Autoantibody-Associated Brainstem Sensory Syndrome and Immune Checkpoint Inhibitors. JAMA Neurol. 2022; 79(9):949-951. PMC: 9274447. DOI: 10.1001/jamaneurol.2022.1824. View

14.

Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H . Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019; 90(8):870-881. DOI: 10.1136/jnnp-2018-320106. View

15.

Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum S, Ishizuka J . Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer. 2020; 126(16):3758-3767. PMC: 7381363. DOI: 10.1002/cncr.32966. View

16.

Dasari S, Tse W, Wang J . Real-world evidence of incidence and outcomes of aplastic anaemia following administration of immune checkpoint inhibitors. Br J Haematol. 2023; 202(6):1205-1208. DOI: 10.1111/bjh.18985. View

17.

Henze L, Buhl C, Sandherr M, Cornely O, Heinz W, Khodamoradi Y . Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes.... Ann Hematol. 2022; 101(3):491-511. PMC: 8810475. DOI: 10.1007/s00277-021-04746-y. View

18.

Graber J, Rosenblum M, DeAngelis L . Herpes simplex encephalitis in patients with cancer. J Neurooncol. 2011; 105(2):415-21. DOI: 10.1007/s11060-011-0609-2. View

19.

Lee H, Park J, Shin S, Kim S, Lee J, Lee A . Herpesviridae viral infections after chemotherapy without antiviral prophylaxis in patients with malignant lymphoma: incidence and risk factors. Am J Clin Oncol. 2011; 35(2):146-50. DOI: 10.1097/COC.0b013e318209aa41. View

20.

Sakoh T, Kanzaki M, Miyamoto A, Mochizuki S, Kakumoto T, Sato K . Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report. BMC Cancer. 2019; 19(1):1220. PMC: 6916037. DOI: 10.1186/s12885-019-6444-0. View